Core Viewpoint - 联康生物科技集团 reported a revenue of HKD 310 million for the first half of 2025, representing a year-on-year growth of 13.4% [1] - The net profit reached HKD 75.955 million, marking a year-on-year increase of 12.7% [1] - The basic earnings per share stood at HKD 0.0127 [1] Revenue Growth Drivers - The increase in profit is attributed to the expansion of the company's sales channels and the growing demand for 博固泰 [1] - There is sustained market interest in the company's existing pharmaceutical products [1] Strategic Focus - The results reflect the company's focus on operational efficiency, strict cost control, and precise commercial execution [1] - This strategic approach has further solidified the company's trajectory of sustained profit growth and long-term value creation [1]
联康生物科技集团发布中期业绩，净利润7595.5万港元，同比增长12.7%